ロード中...
Anti-tumor activity of NLG207 (formerly CRLX101) in combination with enzalutamide in preclinical prostate cancer models
Effective treatments for patients with mCRPC following disease progression on enzalutamide is currently an unmet clinical need. Simultaneous inhibition of the HIF-1α and AR pathways has been shown to overcome enzalutamide resistance in vitro. Combination treatment with NLG207, a nanoparticle-drug co...
保存先:
| 出版年: | Mol Cancer Ther |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8102325/ https://ncbi.nlm.nih.gov/pubmed/33632874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0228 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|